Aligos Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Aligos Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- ALGS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001799448
Board of directors
-
Bridget A. Martell · DirectorSince 2023
-
Carole Nuechterlein · DirectorSince 2023
-
Heather Preston · DirectorSince 2024
-
Jack Nielsen · DirectorSince 2023
-
James Paul Scopa · DirectorSince 2023
-
Lawrence Blatt · Director · President and CEOSince 2023
-
Leonid Beigelman · Director · PresidentSince 2023
-
Margarita Chavez · DirectorSince 2024
-
Peter Hirth · DirectorSince 2023
Chief executives
Lawrence Blatt
· Chief Executive Officer
Dates unknown
Board connections
3 of this board's directors also sit on 6 other boards.
- via Jack Nielsen
- via Bridget A. Martell
- via Bridget A. Martell
- via Jack Nielsen
- via Jack Nielsen
- via Peter Hirth
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 25, 2023 | Carole Nuechterlein Director, 10% owner | Open-market purchase | +7,933,601 | $0.76 | $6,029,537 |
| Oct 25, 2023 | Lawrence Blatt Director, Officer (Chief Executive Officer) | Grant or award | +610,277 | $0.76 | $463,811 |
| Oct 25, 2023 | James Paul Scopa Director | Grant or award | +183,083 | $0.76 | $139,143 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.